Narender Annapureddy, MD
Rheumatology · Nashville, TNNPI 1821302597
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,864 of the $28,685 with a category attached, or 93.7%. GSK accounts for 74.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $12,745 and has fallen 94.1% since, to $746 in 2025.
Across 24 payments — averaging $1195.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$21K
- Novartis$4K
- AstraZeneca$3K
Across 18 payments — averaging $5233.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$80K
- Janssen Research & Development, LLC$14K
What the payments were for
- Consulting fees$26,86494%
- Travel & lodging$1,3875%
- Food & beverage$4342%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 14 | $21,416 |
| Novartis | 4 | $4,230 |
| AstraZeneca | 6 | $3,039 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,685 in reported general payments places this provider in the 85th percentile of 127 rheumatology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 91 | $662,407 |
| Humira(Cf) PenAdalimumab | 80 | $628,142 |
| Orencia ClickjectAbatacept | 65 | $353,251 |
| RinvoqUpadacitinib | 15 | $105,838 |
| Actemra ActpenTocilizumab | 19 | $87,465 |
| Cosentyx Sensoready PenSecukinumab | 12 | $83,573 |
| KineretAnakinra | 14 | $77,582 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $63,234 |
| Mycophenolate Mofetil | 37 | $9,441 |
| Hydroxychloroquine Sulfate | 157 | $5,598 |
| MethotrexateMethotrexate Sodium | 109 | $2,879 |
| Leflunomide | 22 | $2,439 |
| Prednisone | 159 | $1,671 |
| Duloxetine Hcl | 48 | $1,262 |
| Pilocarpine Hcl | 22 | $958 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Nashville
- Victor ByrdNashville$247K
- Christian RheaNashville$81K
- Tyler ReeseNashville$80K
- John BooneNashville$70K
- Simpson TannerNashville$53K
- Erin WilfongNashville$18K
- Robert LagroneNashville$17K
- Poonam SomaiNashville$14K
- Susan HarwellNashville$10K
- Chad BoomershineNashville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.